Oruka Therapeutics (Nasdaq: ORKA), a clinical-stage biotechnology company focused on chronic skin diseases such as plaque psoriasis, will present at the 2026 Jefferies Global Healthcare Conference in New York from June 2-4, 2026.
Oruka’s presentation is scheduled for June 3, 2026 at 3:45 PM ET, with a webcast and replay available on its investor events website.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – ORKA
-0.02%
-0.02%Session close to close
In the May 28 session, ORKA declined 0.02%, reflecting a mild negative market reaction.
This announcement highlights Oruka’s participation in the 2026 Jefferies Global Healthcare Conferenc...
Analysis
This announcement highlights Oruka’s participation in the 2026 Jefferies Global Healthcare Conference, offering additional exposure to institutional investors but not introducing new clinical or financial data. In recent months the company reported strong ORKA-001 psoriasis results, advanced ORKA-002, and executed a large underwritten offering under a $1,000,000,000 shelf. Investors may watch for any new disclosures around the presentation and subsequent clinical milestones or financing moves.
Key Figures
Conference dates:June 2–4, 2026Presentation date:June 3, 2026Presentation time:3:45 PM ET
3 metrics
Conference datesJune 2–4, 20262026 Jefferies Global Healthcare Conference in New York, NY
Presentation dateJune 3, 2026Scheduled Oruka presentation day at Jefferies conference
Presentation time3:45 PM ETScheduled time for Oruka’s conference presentation
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent positive clinical and partnership news correlated with gains, while equity offerings saw negative reactions.
Recent Company History
Over recent months, Oruka reported strong EVERLAST-A Phase 2a data for ORKA-001, showing high complete skin clearance rates, and advanced ORKA-002 into Phase 2 with hidradenitis suppurativa trials planned for 2H 2026. A Halozyme Hypercon collaboration and a large upsized underwritten offering around April 27–30, 2026 expanded funding capacity. Earnings on May 13, 2026 reiterated robust data and cash of $496.0 million. Today’s conference presentation fits into this cadence of clinical and investor-focused updates.
Key Terms
biologics, plaque psoriasis, webcast
3 terms
biologicsmedical
"a clinical-stage biotechnology company developing novel biologics designed to set a new standard"
Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.
plaque psoriasismedical
"for the treatment of chronic skin diseases including plaque psoriasis, today announced its presentation"
A chronic autoimmune skin condition that causes raised, red, scaly patches where the skin sheds too quickly, like a tree producing bark in clumps instead of renewing smoothly. It matters to investors because prevalence, severity, and treatment options drive demand for therapies, shape clinical trial design and regulatory review, and affect potential market size, pricing and reimbursement for drugs or devices aimed at relieving symptoms or altering the underlying immune response.
webcasttechnical
"A webcast and replay of Oruka’s presentations will be available on the Oruka investor events website"
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its presentation at the 2026 Jefferies Global Healthcare Conference, taking place in New York, NY from June 2-4, 2026.
Presentation Details Date: Wednesday, June 3rd, 2026 Presentation Time: 3:45PM ET
About Oruka Therapeutics Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Investor Contact: Alan Lada (650)-606-7911 alan.lada@orukatx.com
FAQ
When will Oruka Therapeutics (ORKA) present at the 2026 Jefferies Global Healthcare Conference?
Oruka Therapeutics will present on Wednesday, June 3, 2026, at 3:45 PM ET. According to Oruka, this presentation is part of the 2026 Jefferies Global Healthcare Conference held in New York from June 2-4, 2026.
How can investors watch the Oruka Therapeutics (ORKA) presentation from the 2026 Jefferies Global Healthcare Conference?
Investors can watch via a webcast available on Oruka’s investor events website. According to Oruka, both a live webcast and a replay of the conference presentation will be accessible at https://ir.orukatx.com/news-events/events-presentations.
Where is the 2026 Jefferies Global Healthcare Conference featuring Oruka Therapeutics (ORKA) being held?
The 2026 Jefferies Global Healthcare Conference is being held in New York, NY. According to Oruka, the event runs June 2-4, 2026, with the company’s session scheduled for June 3 at 3:45 PM ET.
What type of company is Oruka Therapeutics (ORKA), presenting at the 2026 Jefferies Global Healthcare Conference?
Oruka Therapeutics is a clinical-stage biotechnology company developing novel biologics for chronic skin diseases. According to Oruka, its pipeline targets conditions including plaque psoriasis, and the company will highlight its work at the 2026 Jefferies Global Healthcare Conference.
Where can shareholders find the replay of Oruka Therapeutics’ (ORKA) June 3, 2026 conference presentation?
Shareholders can access the replay on Oruka’s investor events website. According to Oruka, the webcast and replay for the June 3, 2026, 3:45 PM ET Jefferies Global Healthcare Conference presentation will be hosted at https://ir.orukatx.com/news-events/events-presentations.
